IBT
MRTX

International Biotechnology Trust’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

International Biotechnology Trust’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$9.4M Sell
216,000
-44,000
-17% -$1.57M 3.17% 10
2023
Q2 		$9.39M Buy
260,000
+16,000
+7% +$659K 2.86% 13
2023
Q1 		$9.07M Hold
244,000
– – 2.53% 14
2022
Q4 		$11.1M Buy
244,000
+108,000
+79% +$6.99M 3.41% 9
2022
Q3 		$9.5M Buy
136,000
+126,869
+1,389% +$9.39M 3.05% 11
2022
Q2 		$136K Sell
9,131
-179,369
-95% -$11.4M 1.42% 22
2022
Q1 		$1.37M Buy
188,500
+62,000
+49% +$6.34M 0.31% 50
2021
Q4 		$18.5M Buy
126,500
+28,000
+28% +$4.35M 4.13% 7
2021
Q3 		$17.4M Buy
98,500
+81,600
+483% +$13.1M 4.2% 8
2021
Q2 		$2.73M Sell
16,900
-50,500
-75% -$8.11M 0.72% 32
2021
Q1 		$11.5M Hold
67,400
– – 3.05% 14
2020
Q4 		$14.8M Buy
67,400
+40,500
+151% +$8.76M 4.04% 11
2020
Q3 		$4.46M Sell
26,900
-17,000
-39% -$2.33M 1.44% 21
2020
Q2 		$5.03M Hold
43,900
– – 1.67% 21
2020
Q1 		$3.37M Buy
43,900
+8,000
+22% +$717K 1.54% 17
2019
Q4 		$4.63M Buy
35,900
+25,000
+229% +$2.41M 1.67% 22
2019
Q3 		$849K Hold
10,900
– – 0.39% 44
2019
Q2 		$1.12M Sell
10,900
-10,800
-50% -$841K 0.42% 48
2019
Q1 		$1.59M Buy
+21,700
New +$1.48M 0.59% 45

Other funds holding MRTX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

International Biotechnology Trust's MRTX Position: Q3 2023 in Review

International Biotechnology Trust reduced its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 17% in Q3 2023, selling an estimated $1.57M and leaving 216,000 shares worth $9.4M. The position accounts for 3.17% of the portfolio, ranked #10.

International Biotechnology Trust first reported a position in MRTX in Q1 2019 and has held it in 19 quarters since. The position peaked at $18.5M in Q4 2021. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

  • International Biotechnology Trust held 216,000 shares of Mirati Therapeutics, Inc. Common Stock worth $9.4M as of Q3 2023.
  • International Biotechnology Trust sold 44,000 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.57M.
  • Mirati Therapeutics, Inc. Common Stock made up 3.17% of International Biotechnology Trust's portfolio in Q3 2023, its #10 holding.
  • International Biotechnology Trust first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and has held it in 19 quarters since.
  • International Biotechnology Trust's Mirati Therapeutics, Inc. Common Stock position peaked at $18.5M in Q4 2021.
  • 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.